I believe LTUS will grow at a much more rapidly than that for a number of reasons.
1) I think that their current offerings will grow at that pace and they have several other drugs in the pipeline that focus on chronic illnesses, diabetes, hypertension and asthma - The last of which R-Bambuterol is expected to reach 50 million a year in sales.
2) The OTC division is in its infancy an should grow near 100% a year as they add more customers and product offerings.
3) The inner Mongolian facility will have a capacity of 240 million bottles of IV fluids a year. Even at half capacity that is still $360 million a year in sales.
4) Once the building is done, LTUS intends to grow through M&A, focusing on new products, new distribution and a marketing arm.
LTUS's conservative guidance says 25% a year, but by their actions their sights are set much higher.